ModifiedUnitedHealthcarePolicy CSNCT0335.03

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for North Carolina Only)

This policy governs the use of cytologic analysis of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) for breast cancer screening or diagnosis in North Carolina; it applies to providers and coverage determinations for UnitedHealthcare members in NC.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for North Carolina Only)

Policy CodePolicy CSNCT0335.03

Change TypeState-specific versionsupporting information updated

Effective DateAug 1, 2025

Next Review Date

Key ActionDo not use ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for breast cancer screening or diagnosis; follow standard imaging and established diagnostic pathways and document procedure details if submitted.

SourceLink

POLICY UPDATE CHANGES

Created state-specific policy version for the state of North Carolina (no change to coverage guidelines).

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

3procedures addressed

1applicable state

19499example CPT (ref)

NCCN (2025)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

94%pooled sensitivity (DSany)

47%pooled specificity (DSany)

Coverage Determination

Unproven / Not Medically Necessary

Not medically necessary / Unproven for screening or diagnosis

Main policy stance: Ductal lavage, breast ductal fluid aspiration and cytology (including nipple aspirate fluid), and fiberoptic ductoscopy (with or without ductal lavage) are considered unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery due to insufficient evidence of efficacy.

Supported by evidence of low sensitivity, high rates of inadequate samples, limited ductal visualization, and lack of demonstrated improvement in cancer detection rates or mortality; practice guidelines do not recommend DL.

Clinical evidence summary

Summary of clinical evidence relevant to diagnostic utility in PND

NAF cytology and image analysis findings: NAF cytology demonstrates low sensitivity and substantial sample inadequacy; in a prospective study sensitivity for NAF and MD cytology was 10% and 14% respectively in a PND/lesion cohort, but specificity in non-PND cohorts was 100%. Combining NAF/MD cytology with image analysis increased sensitivity (to 45% with aneuploidy analysis; best combined model 55% sensitivity and 100% specificity) though studies were small and uncontrolled.

Findings limited by small sample sizes, potential false positives in PND from intraductal papilloma, and high rates of inadequate samples in systematic reviews.

FDS diagnostic performance and limitations: FDS studies are heterogeneous (single-center, retrospective or small RCTs) and mainly assess technical success and diagnostic accuracy. A systematic review pooled DSany sensitivity 94% and specificity 47%, while DSsusp sensitivity 50% and specificity 83%, indicating good detection of malignancy but poor discrimination between benign and malignant findings. Clinical applicability is limited by variable definitions, study heterogeneity, and incomplete reporting.

No high-quality evidence FDS improves detection rates, earlier stage at diagnosis, or breast cancer mortality; procedure is technically challenging and examines only a portion of the ductal system.

Large and single-center cohort findings: Large retrospective series report high concordance between FDS findings and pathology for elevated and non-elevated lesions and suggest potential to reduce surgery for benign lesions; example cohorts reported high kappa concordance indices and malignancy detection rates (Zhang et al. 2020; Zhang et al. 2025), but are limited by single-center, retrospective designs.

Reported diagnostic concordance and malignancy detection rates do not substitute for prospective outcome data demonstrating improved clinical endpoints.

HFUS compared with FDS: In a retrospective study of 210 participants with PND, HFUS and FDS had similar overall diagnostic accuracy (83.87% vs 85.08%). Authors recommend HFUS as preferred noninvasive evaluation when lesions are visualized, reserving FDS when HFUS cannot reveal lesion location or extent; combining HFUS with FDS increased accuracy.

Study limited by retrospective, single-center design; prospective trials are needed.

Intraoperative methylene blue with FDS: Immediate methylene blue injection after FDS and prior to selective ductectomy may improve identification of discharging ducts and intraductal lesions without overflow if surgery is performed within 12–24 hours; a retrospective series reported an overall malignancy detection rate of 14% in 164 patients with PND.

Single-center retrospective data; authors call for larger studies to confirm optimal timing and clinical impact.

Safety, feasibility, and technical limitations: Ductoscopy may be unsuccessful in approximately 30% of cases due to narrow or occluded ducts, perforation, prior procedures, or anatomic factors. Reported complications are generally mild (pain, mastitis), with rare major complications; randomized trial data showed no serious adverse events but were underpowered for clinical outcomes.

Technical failure rates and limited ductal access constrain generalizability and routine use.

The following procedures are considered unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery due to insufficient evidence of efficacy: breast ductal lavage, breast ductal fluid aspiration and cytology (including nipple aspirate fluid), and fiberoptic ductoscopy (with or without ductal lavage). This policy reflects available evidence that these techniques have not been shown to provide reliable diagnostic benefit when added to standard care.

Published evidence on fiberoptic ductoscopy (FDS) is largely limited to preliminary cross-sectional and feasibility studies assessing intraductal visualization and diagnostic accuracy. The procedure is invasive, technically challenging, and examines only a small portion of the ductal system. There is no high‑quality evidence demonstrating that ductoscopy improves breast cancer detection rates, leads to earlier stage at diagnosis, or reduces breast cancer mortality; therefore outcome benefits remain unproven and further studies are required.

Ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy are considered not medically necessary for breast cancer screening or diagnosis. Studies have shown limitations including low sensitivity, high rates of inadequate samples, and insufficient evidence that use of these techniques improves clinical outcomes, so they should not be used routinely for screening or diagnostic evaluation in place of established methods.

Fiberoptic ductoscopy has important technical limitations that inform its exclusion from routine use: it is technically challenging, can be uncomfortable for patients, and has a steep learning curve; only a small portion of the ductal system can be examined and peripheral lesions are often inaccessible. Because of these constraints and the lack of high‑quality outcome data, FDS is not supported as a routine screening tool or as an intervention that reduces mortality.

Coding Reference

Applicable CPT Codes (reference)CPT

19499

Unlisted procedure, breast

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization may be required for procedures related to ductal fluid cytology, ductal lavage, nipple aspiration, and fiberoptic ductoscopy per the member's benefit plan. Providers should verify and obtain any required prior authorization before performing these services.

Verify prior authorization requirements with the member's benefit plan before scheduling procedures
Obtain prior authorization when required by the member's plan or applicable federal/state/contractual rules

Note

Reference Applicable Plan Requirements

Decisions regarding coverage and claims must reference the applicable federal, state, or contractual benefit plan requirements, which govern in the event of a conflict with this policy. This policy is informational and may not override specific plan terms or legal mandates.

When a member's plan differs from this policy, follow the federal, state, or contractual requirements that apply
In event of conflict, federal/state/contractual requirements supersede this Medical Policy

Background and Scope

Cytologic examination of epithelial cells from breast ductal fluids has been investigated as a potential early indicator of breast cancer. Fluid can be collected by ductal lavage (microcatheter cannulation), nipple aspiration (aspiration or fine needle), or obtained during fiberoptic ductoscopy, which also allows intraductal visualization. Available evidence shows low sensitivity, substantial rates of inadequate samples, and methodological limitations in studies to date. While small studies report biologic findings (for example, microRNA differences in lavage fluid), there is currently no demonstration that routine cytologic assessment of ductal fluid leads to earlier detection or improved survival; further longitudinal validation is needed.

Definitions

Ductal lavage (DL) — definition and method description

DefinitionDuctal lavage (DL) — an invasive procedure that removes ductal fluid by inserting a microcatheter into the breast ducts via the nipple to collect epithelial cells for cytologic analysis.

Method (brief)Fluid is obtained by cannulating individual lactiferous ducts with a microcatheter and lavaging the ductal lumen to recover epithelial cells and ductal fluid for cytologic evaluation.

Clinical contextStudied as a potential early indicator for breast cancer but not recommended for routine screening or diagnosis due to limited diagnostic performance and inadequate evidence of outcome benefit.

Nipple aspirate fluid (NAF) — aspiration-collected fluid used for cytologic/molecular testing

DefinitionNipple aspirate fluid (NAF) — fluid collected from the nipple via aspiration (noninvasive aspiration or fine-needle aspiration) used for cytologic or molecular analysis.

Policy Revision History

2025-11-01state_version_created

Created state-specific policy version for North Carolina; no change to coverage guidelines.

2025-08-01supporting_information_updatedLatest

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for North Carolina Only)

Policy CodePolicy CSNCT0335.03

Change TypeState-specific versionsupporting information updated

Effective DateAug 1, 2025

Next Review Date

SourceLink

On This Page

Denial Risk

Denial Risk for Investigational/Unproven Procedures

Ductal lavage, nipple aspiration/ductal fluid cytology, and fiberoptic ductoscopy are considered investigational/unproven for breast cancer screening or diagnosis due to insufficient evidence. Submissions for these procedures used for screening or diagnostic purposes risk denial if they are inconsistent with the member's benefit terms.

Ductal lavage (DL) — considered unproven and not medically necessary for screening or diagnosis
Breast ductal fluid aspiration and cytology — considered unproven and not medically necessary for screening or diagnosis
Fiberoptic ductoscopy (FDS), with or without ductal lavage — considered unproven and not medically necessary for screening or diagnosis
Risk of claim denial if procedures are billed for screening or diagnostic use when considered investigational under the benefit plan

Documentation Required

Documentation Expectations

If a procedure is submitted for consideration (e.g., for a covered compassionate or investigational exception), include detailed documentation to support medical necessity.

Document method of collection (ductal lavage, nipple aspiration, fine needle aspiration, fiberoptic ductoscopy)
Provide detailed procedure notes including indication, technique, laterality, and findings
Attach relevant clinical history, imaging results, and prior conservative management or diagnostic attempts

Step Therapy

Step Therapy / Other Utilization Management

There are no step therapy requirements specified in this policy. Providers should follow any plan-specific utilization management rules.

No step therapy specified for these procedures in this policy
Follow member's benefit plan for any additional utilization management (e.g., step edits, quantity limits)

Note

Follow Member's Benefit Plan

Follow the member's benefit plan for any prior authorization requirements and other coverage determinations. This Medical Policy does not replace or supersede plan-specific rules.

Check plan-specific benefit language before rendering services
Reference plan contract, state mandates, and federal requirements as applicable

UseNAF specimens can be evaluated with cytology and adjunctive image analysis (aneuploidy) to detect atypical cells as potential markers of malignancy.

LimitationsStudies report low sensitivity in some cohorts and potential false positives in participants with pathologic nipple discharge (PND).

Fiberoptic ductoscopy (FDS) — brief definition and technical challenge

DefinitionFiberoptic ductoscopy (FDS) — use of a very thin endoscope to directly visualize the breast ducts and to obtain ductal fluid or tissue for evaluation.

Technical noteFDS is technically challenging, can be uncomfortable, has a steep learning curve, examines only a small portion of the ductal system, and peripheral lesions are often inaccessible.

Clinical evidenceAvailable evidence is limited to preliminary cross-sectional and single‑center studies; no high‑quality data show improved cancer detection rates or mortality benefit.

Nipple aspirate fluid (NAF) — cytologic evaluation and image analysis

Definition (alternative)Nipple aspirate fluid (NAF) — nipple-collected fluid analyzed by cytologic evaluation and image analysis (e.g., aneuploidy) to detect atypical cells and improve detection performance when combined with ductoscopic specimens.

Diagnostic performanceCombining NAF cytology with ductoscopy cytology and image analysis has increased sensitivity in small studies (e.g., combined model up to 55% sensitivity with 100% specificity in a non-PND cohort).

Study limitationsFindings derive from small, uncontrolled studies and may be affected by false positives in PND due to intraductal papillomas.

Fiberoptic ductoscopy (FDS) — intraductal visualization and lesion localization

Definition (intraductal visualization)Fiberoptic ductoscopy (FDS) — an invasive intraductal endoscopic technique to visualize the mammary ductal system, identify intraductal lesions, and assist in localization for selective duct excision.

Adjunct techniquesMay be combined with intraoperative methylene blue injection after FDS to aid identification and localization of discharging ducts and lesions for surgery (timing 12–24 hours before ductectomy reported).

Limitations for routine useOnly a small portion of the ductal system is accessible; evidence is limited and does not demonstrate improved detection or mortality outcomes, limiting routine adoption.

Pathologic nipple discharge (PND) — definition

Definition (PND)Pathologic nipple discharge (PND) — spontaneous, unilateral, bloody or serous nipple discharge that is suspicious for intraductal pathology and prompts diagnostic evaluation.

Associated evaluationPND commonly prompts evaluation with imaging, cytology (NAF or ductal samples), and may prompt consideration of ductoscopy for localization when noninvasive imaging is inconclusive.

Clinical considerationsNAF and ductoscopic cytology have lower accuracy in PND and can produce false positives due to intraductal papillomas; HFUS is often recommended as the preferred noninvasive initial evaluation when lesions are visualized.